@article{3a7e94758a424d9481e075717cbce8a5,
title = "C5 inhibitor avacincaptad pegol treatment for geographic atrophy: A comprehensive review",
abstract = "Geographic atrophy (GA) remains a leading cause of central vision loss with no known cure. Until recently, there were no approved treatments for GA, often resulting in poor quality of life for affected patients. GA is characterized by atrophic lesions on the retina that may eventually threaten the fovea. Emerging treatments have demonstrated the ability to reduce the rate of lesion growth, potentially preserving visual function. Avacincaptad pegol (ACP; Astellas Pharma Inc), a complement component 5 inhibitor, is an FDA-approved treatment for GA that has been evaluated in numerous clinical trials. Here we review the current clinical trial landscape of ACP, including critical post hoc analyses that suggest ACP may reduce the risk of severe loss among patients with GA.",
keywords = "C5 inhibition, age-related macular degeneration (AMD), aptamer, avacincaptad pegol (ACP), complement, geographic atrophy (GA), retinal disease",
author = "Danzig, {Carl J.} and Khanani, {Arshad M.} and Anat Loewenstein",
note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.",
year = "2024",
doi = "10.1080/1750743X.2024.2368342",
language = "אנגלית",
volume = "16",
pages = "779--790",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "12",
}